Published On:
Mon, May 4th, 2015
Mylan chairman due $72 million golden parachute
Mylan's filing on executive compensation reveals much higher pay than at Teva.
Mylan (MYL), the generic pharmaceuticals company that is now the object of a hostile takeover bid from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA), reported its senior executives’ compensation at the end of last week. The report is interesting in the light of the exchange between the two companies over the takeover bid. Mylan chairman Robert Coury’s rejection of Teva’s bid cast aspersions on Teva’s corporate culture… [READ MORE]
Published by Globes [online], Israel business news – www.globes-online.com
Read more about: Asia, Business, Business/Finance, Executive pay, Health/Medical/Pharmaceuticals, Middle East, Mylan Inc, Mylan’, Science and technology in Israel, takeover, Tel Aviv stock exchange, Teva Pharmaceutical Industries, TEVA PHARMACEUTICAL INDUSTRIES LIMITED